New drug may boost survival for advanced prostate cancer patients

A new clinical trial conducted at the Knight Cancer Center at Oregon Health and Science University indicates that the drug enzalutamide "blocks male hormone activity [and] can improve survival and delay the need for chemotherapy" in men with advanced prostate cancer. According to senior study author Dr. Tomasz Beer, men who received enzalutamide on a daily basis started chemotherapy 17 months later than those who received a placebo. To learn more about this study, presented on June 1, 2014 at the American Society of Clinical Oncology meeting in Chicago, click here.